Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS awarded tenders worth R22,5 million for Maths and Science teacher-training
2010-03-17

The Centre for Education Development (CED) at the University of the Free State (UFS) has received tenders worth about R22,5 million over the past two years from four provinces to train Mathematics and Science teachers from underperforming schools.

The CED has received tenders from the following provincial departments of education: Free State, Northern Cape, North West and Mpumalanga.

“The centre has a good reputation for the training of teachers in these disciplines and has been involved with the upgrading of Maths and Science teachers for at least 15 years,” said Prof. Daniella Coetzee, Director of the CED.

It is currently busy with the training of North West teachers after being awarded a R13,5 million tender by the Province as part of its quest to improve pass rates in Mathematics and Natural and Physical Sciences in underperforming schools.

“The tender is for the upgrading of the knowledge and methodology of teachers for Mathematics and Natural and Physical Science, as well as the upgrading of the knowledge of subject specialists in the North West Province,” said Prof. Coetzee.

For this project the centre trains 1 000 teachers and 90 subject specialists from underperforming schools over a period of three years.

The programme commenced in February this year with a baseline assessment of the teachers to determine knowledge and methodology gaps upon which to focus in the training.

“After the programme has been completed we will also do a post-assessment to see if there had been progress,” she said.

The training is offered only on Saturdays at Vryburg, Klerksdorp, Makapanstad, Brits and Zeerust and is presented by lecturers from the CED as well as selected and trained tutors from the North West province.

“We have successfully completed another Maths, Science and Technology project for the North West Department of Education. We have also completed similar projects for the Northern Cape and one for the Free State Department of Education,” she said.

These completed projects entailed formal qualifications (Advanced Certificate in Education) in Maths, Science and Technology and were worth in excess of R5 million.

The CED has just been recently awarded yet another tender in excess of R4 million over a period of two years by the Mpumalanga Department of Education.

Prof. Coetzee had the following to say about the CED being the preferred choice of these provincial Departments of Education: “It has to do with the fact that the CED has been performing well with the upgrading of teachers. It has proven itself as a leader in the in-service training of Maths and Science teachers in South Africa.”

Media Release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt@ufs.ac.za  
17 March 2010

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept